NCT06279728: Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients |
|
|
| Available | N/A | | US | Datopotamab deruxtecan, Dato-DXd, DS-1062a | Daiichi Sankyo, AstraZeneca | EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer | | | | |